Trial Profile
A Randomized, Observer-blinded, Parallel-group, Active-control, Phase I/II Trial Of The Safety, Immunogenicity, And Tolerability Of 20 µg, 60 µg, And 200 µg Of Meningococcal Group B Rlp2086 Vaccine In Healthy Children And Adolescents Aged 8 To 14 Years
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Dec 2014
Price :
$35
*
At a glance
- Drugs PF 5212366 (Primary) ; Hepatitis A-hepatitis B vaccine
- Indications Meningococcal group B infections
- Focus Pharmacodynamics
- Sponsors Wyeth
- 23 Jan 2008 The expected completion date for this trial is now 1 Jan 2008.
- 21 Nov 2006 New trial record.